Tag:
Incivek
Latest Headlines
Latest Headlines
CDC delivers gift to hep C drugmakers
The recommendation by the CDC that the 70 million U.S. baby boomers all be tested for hepatitis C is a big gift for the newest hep C treatments.
Vertex chief's pay dropped to $13.4M last year
Outgoing Vertex Pharmaceuticals CEO Matthew Emmens saw his 2011 compensation drop slightly, despite the company's successful launch of its new hepatitis C drug, Incivek.
Vertex vows to race ahead with interferon-free combo for hep C
Vertex ( $VRTX ) today unveiled a slate of somewhat positive interim midstage results for an all-oral combo regimen that includes its game-changing drug Incivek .
Merck says Victrelis can interfere with HIV meds
Merck ( $MRK ) has notified doctors that its new hepatitis C drug Victrelis interferes with commonly used AIDS drugs. Victrelis can reduce the effectiveness of the HIV-fighters--and vice-versa--Merck...
Vertex backs up pricey new CF drug with co-pay help
Vertex Pharmaceuticals ( $VRTX ) achieved another major milestone with FDA's approval of its cystic fibrosis therapy Kalydeco. The "breakthrough" product is the first to address CF's...
Merck spinout nails promising study on hep C vaccine
A group of European investigators working in league with a small biotech spun out of Merck ( $MRK ) four years ago has claimed an early-stage success with a small human trial that has generated
Interview: Vertex CEO worries about 'hyper-focus' on hep C
No question that Vertex Pharmaceuticals ( $VRTX ) needs another hit to follow its new hepatitis C drug Incivek. But that's just one of the things on the to-do list for incoming CEO Jeffrey Leiden, who
Interview: Vertex CEO concerned about investors' 'hyper-focus' on hep C
Matthew Emmens
On the heels of Vertex Pharmaceuticals' ( $VRTX ) big news last week about changing CEOs next year, FierceBiotech chatted with both current chief executive Matt Emmens
Vertex's new leader expected to diversify
Vertex Pharmaceuticals ( $VRTX ) will be getting its second new leader in two years as it seeks to become a more diversified drug company. Former Abbott Laboratories executive Jeffrey Leiden will
Vertex CEO stepping down after banner year
Apparently, Matthew Emmens wanted to announce his departure from his CEO post at Vertex Pharmaceuticals ( $VRTX ) at what could be considered the pinnacle of his tenure at the company. Emmens, who was
